The limited localization and penetration of monoclonal antibodies (mAb) into solid tumors restricts their antitumor efficacy. Here, we describe a solid tumor-targeting antibody with enhanced tumor penetration activity. We designed a 22-residue peptide (A22p), which was extracted from the C-terminal basic region of semaphorin 3A (Sema3A) but modified to have higher affinity with neuropilin receptors (NRP), and genetically fused it to the C-terminus of Fc of human immunoglobulin G1 via a 15-residue (G 4 S) 3 linker, generating FcA22p, for the bivalent binding to NRPs. In contrast to Fc or the monovalent A22p peptide alone, Fc-A22p homed to tumor vessels and induced vascular permeability through VE-cadherin downregulation and penetrated tumor tissues by interacting with NRPs in mice bearing human tumor xenografts. We extended the Fc-A22p platform by generating mAb-A22p antibodies of two clinically approved solid tumor-targeting mAbs, the anti-EGF receptor mAb cetuximab (erbitux), and the anti-Her2 mAb trastuzumab (herceptin). The mAb-A22p antibodies retained the intrinsic antigen binding, natural Fc-like biophysical properties, and productivity in mammalian cell cultures, comparable with those of the parent mAbs. In mouse xenograft tumor models, the mAb-A22p antibodies more efficiently homed to tumor vessels and spread into the extravascular tumor parenchyma, which significantly enhanced antitumor efficacy compared with the parent mAbs. Our results suggest that mAb-A22p is a superior format for solid tumor-targeting antibodies due to its enhanced tumor tissue penetration and greater antitumor efficacy compared with conventional mAbs.
Introduction
Poor localization and penetration of monoclonal antibodies (mAb) into solid tumors is one of main mechanisms of limiting tumor response to antibody therapy (1, 2) . For example, mAb accumulation in tumors of patients is typically very inefficient, in the order of 0.001% to 0.01% of the injected dose per gram of tumor (2) (3) (4) . For anticancer mAbs targeting antigens expressed on solid tumors, systemically administered mAbs need to selectively localize to tumor vessels, cross the blood vessels into the tumor parenchyma, and then penetrate into tumor tissues across the interstitium by diffusion or convection to reach as many tumor cells as possible (2) (3) (4) . However, the abnormal physiologic and physical properties of solid tumors, such as the defective blood vessels, lack of lymphatic drainage, and extracellular matrix components, limit the extravasation of mAbs from blood vessels and spread within tumor tissues (3) (4) (5) . In addition, the intrinsic properties of mAbs, including the relatively large size (approximately 150 kDa) and high-affinity antigen binding, may restrict vascular extravasation and transport within tumor tissue (3, 5) .
Several antibody-engineering approaches have been used to improve the tumor tissue penetration of mAbs, including manipulations of molecular size, charge, valency, and antigen-binding affinity (6) . Another approach includes the coadministration of mAbs with so-called promoter agents that enhance vascular permeability and/or reduce epithelial barriers, which leads to improved tumor tissue penetration of bloodborne mAbs (reviewed in refs. 2, 5) . For example, coadministration of an internalizing Arg-Gly-Asp (iRGD) tumor-penetrating peptide (7) (8) (9) and a viral protein called epithelial junction opener-1 (JO-1; ref. 10) significantly enhanced tumor penetration and antitumor efficacy of the anti-Her2 mAb trastuzumab (Herceptin) and the anti-EGF receptor (EGFR) mAb cetuximab (Erbitux), respectively, in mouse xenograft tumor models.
In this study, we sought to develop a format of solid tumor-targeting antibody with enhanced vascular extravasation and tumor penetration activity. We achieved this by fusing mAbs to a tumor-penetrating peptide that targets tumor-associated proteins. For the target protein, we chose a neuropilin receptor (NRP) because NRPs are abundantly expressed on the surface of many tumor endothelial and epithelial cells (11) and can increase vascular permeability upon activation by their intrinsic ligands (12, 13) . Further, some NRP-binding peptides have been shown to improve tumor tissue penetration of coadministered anticancer drugs, including mAbs (8, 14) . Human NRP1 and NRP2 (NRP1/2), which share 44% sequence identity, are coreceptors of plexin receptors for secreted class 3 semaphorin (Sema3) ligands, and are coreceptors of VEGF receptors (VEGF-R) for VEGF ligands (11, 15) . In addition to the ligand-specificity determining a1a2 domains, NRP1/2 have a specific C-terminal arginine-binding pocket on the b1 domain, which is the shared binding site for furin-processed Sema3 and VEGF ligands with a C-terminal Arg residue (see Supplementary Fig. S1A-S1C for details; refs. 16, 17) and for peptides with Arg/Lys-rich C-terminal motifs (9, 18) .
Sema3A, a prototype Sema3 ligand, increases vascular permeability (12) . However, unlike VEGF, Sema3A suppresses VEGF-mediated angiogenesis and induces tumor vascular normalization (19, 20) . Therefore, we designed an NRP-targeting 22-mer peptide (A22p) based on the Cterminal basic tail of Sema3A, but we modified it to have higher affinity for NRPs. When A22p was genetically fused to the C-terminus of Fc to generate Fc-A22p and administered, we found that Fc-A22p induced vascular permeability and penetrated into tumor tissues by interacting with NRPs. We further explored the Fc-A22p platform with 2 clinically available solid tumor-targeting mAbs, the anti-EGFR cetuximab, and the anti-Her2 trastuzumab. We demonstrated that administration of these 2 mAbs as mAb-A22p antibodies improved tumor tissue penetration and antitumor efficacy in xenograft tumor models compared with the parent mAbs, providing a superior antibody format for solid tumor therapy.
Materials and Methods

Cell lines
Human umbilical vein endothelial cells (HUVEC) purchased from Innopharmascreen were maintained in complete endothelial growth medium-2 (EGM-2; PromoCell) and, if necessary, starved in endothelial basal medium-2 (EBM-2; PromoCell). HUVECs at passages from 3 to 8 were used throughout the study. Human cancer cell lines, SK-OV-3 (Ovary), A431 (Epidermis), and FaDu (Pharynx) cells were purchased from Korean Cell Line Bank where they were characterized by DNA fingerprinting. SK-OV-3 and A431 cell lines were cultured in RPMI1640 (Welgene; ref. 21) . FaDu cell lines were cultured in Minimum Essential Media (MEM; Welgene). PPC-1 cell lines were obtained from Prof. Keesook Lee (Chonnam National University, Korea) and cultured in Dulbecco's modified eagle media (DMEM; Welgene; ref. 22) . Media were supplemented with 10% (v/v) heat inactivated FBS (Welgene), 100 units/mL of penicillin, and 100 mg/mL of streptomycin (Welgene). All of the cell lines were maintained at 37 C in a humidified 5% CO 2 incubator and routinely screened for Mycoplasma contamination (CellSafe).
Construction, expression, and purification of antibodies DNA encoding human immunoglobulin G1 (IgG1) Fc (hinge-CH2-CH3, residues 225-447 in EU numbering) was subcloned into pcDNA3.4 vector (Invitrogen) for Fc expression (23) . The heavy and light chains of the anti-EGFR mAb cetuximab (24) and the anti-Her2 mAb trastuzumab (25) were subcloned into pcDNA3.4 vector (Invitrogen) using a combination of gene synthesis and overlapping PCR. Fc-A22/-A22p or mAb-A22p was constructed by cloning the peptide and (G 4 S) 3 linker in frame at the end of the Fc. Antibodies were produced by transient transfection of the plasmids into HEK293F cells using the Freestyle 293-F expression and media system (Invitrogen), as we described before (23) . Antibodies were purified from the culture supernatants using a Protein-A agarose chromatography column (GE Healthcare; ref. 26 ).
Confocal immunofluorescence microscopy of cells
Confocal immunofluorescence microscopic analyses were performed as described (27) . Cells (5 Â 10 4 cells/ well) grown overnight on coverslips in 24-well culture plates were washed, incubated in serum-free transfection optimized medium (TOM; Welgene) for 30 minutes at 37 C, and then treated with proteins diluted in TOM medium at 37 C for the indicated periods. After washed 2 times with cold PBS, cells were fixed with 2% paraformaldehyde in PBS for 10 minutes at 25 C, and then permeabilized with Perm buffer [0.1% saponin, 0.1% sodium azide, 2% bovine serum albumin (BSA) in PBS] for 10 minutes at 25 C. After blocking with 2% BSA in PBS for 1 hour at 25 C, internalized proteins were detected with fluorescein isothiocyanate (FITC)-conjugated anti-human IgG for 1 hour at 25 C. In the colocalization assay with NRP1 or NRP2, the primary antihuman/mouse/rat/monkey NRP1 (Abcam) or antihuman/mouse/rat NRP2 antibody (Santa Cruz Biotechnology) was additionally incubated overnight at 4 C before the detection with the secondary antibody tetramethylrhodamine (TRITC)-conjugated anti-rabbit IgG (Sigma) for 1 hour at 25 C. After mounting the coverslips onto glass slides with VECTASHIELD [mounting medium with 4 0 ,6-diamidino-2-phenylindole (DAPI), Vector Laboratories], optical confocal sections were obtained on a Zeiss LSM710 systems with the ZEN software (Carl Zeiss).
Endothelial permeability assay
Permeability across endothelial cell monolayers was assessed using HUVECs as previously described (13, 28 3 (after 5-7 days growth), mice were randomized into each groups (n ¼ 7 per group) and administered intravenously via tail vein in a dose/ weight-matched fashion every 3 days (total, 6 times) with proteins or antibodies, as specified in the figure legends. Tumor length and width were measured every 3 days using calipers, and tumor volumes were calculated by the formula 1 / 2 Â length Â width 2 (26) . The statistical significance was evaluated by one-way analysis followed by two-tailed Student t tests on Excel Software (Microsoft Inc.).
Immunofluorescence of tumor tissues
A single dose of Fc proteins (2.5 mg/kg), antibodies (2.5 mg/kg), or biotinylated A22 or A22p peptides (5 mg/kg) was intravenously injected into mice bearing FaDu, SK-OV3, or A431 xenografted tumors with an average size of approximately 7 to 8 mm in diameter. Tumor tissues were harvested 3 or 12 hours postinjection. The preparation of tumor tissue section and immunofluorescence staining of the cryosections were performed as described before (29, 30) . Briefly, the excised tumors from mice were fixed in 4% paraformaldehyde overnight at 4 C, cryoprotected in 30% sucrose for 10 hours, and then frozen in optimum cutting temperature (OCT; Tissue-Tek) embedding medium. For immunofluorescence staining, cryosections were prepared at 10 mm thickness and incubated with blocking solution (2% BSA in PBS) for 1 hour at 25 C. Tissue sections were stained with FITC-conjugated anti-human IgG (Sigma) in 2% BSA in PBS for 1.5 hours at 25 C in dark to detect Fc proteins or antibodies, and then washed 3Â with PBST (PBS with 0.1% Tween 20; 10 minutes each wash). After another blocking step with blocking solution (2% BSA in PBS) for 1 hour at 25 C, tissue sections were also stained with rat anti-mouse CD31 mAb, rabbit anti-human/mouse/rat NRP1 (Abcam), or rabbit anti-human/mouse/rat/monkey NRP2 antibody (Santa Cruz Biotechnology) in 2% BSA in PBS at 4 C overnight, washed 3Â with PBST and then stained with goat anti-rat TRITC-conjugated antibodies (Millipore), FITC-conjugated anti-human IgG Fc antibody, or streptavidin-FITC (Invitrogen) at 25 C for 1.5 hours in dark. Slides were then washed 3Â with PBST and then mounted in VECTASHIELD. Tissue sections were examined by Ziess LSM710 systems with the ZEN software (Carl Zeiss). Fluorescence images in each tissue were quantified for positive area of Fc-or streptavidin (SA)-staining with the ImageJ software (NIH).
In vivo permeability assay
Female BALB/c athymic nude mice bearing preestablished FaDu tumor (about 1 cm in diameter) were injected intravenously with Fc proteins (150 mg), VEGF165 (400 ng), and Sema3A (400 ng) combined with 1 mg of Evans Blue (Sigma) in PBS. After 40 minutes of circulation, the mice were perfused through the heart with PBS containing 1% BSA, and tumors were collected (n ¼ 3 per group). For Evans Blue quantification, the dye was extracted from tumors in 1 mL of 2,2,-N-methylformamide (Sigma) for overnight at 37 C with mild shaking and quantified by measuring the absorbance at 600 nm with a spectrophotometer (8) .
Statistical analysis
Data are reported as the mean AE SD of at least 3 independent experiments, unless otherwise specified. Comparison between two groups was analyzed for statistical significance by a two-tailed unpaired Student t test in Sigma Plot 8.0 software (SPSS Inc.). A P value of less than 0.05 was considered statistically significant.
Details of reagents, recombinant protein expression and purification, construction, expression, and purification of antibodies, binding analysis by ELISA, surface plasmon resonance (SPR), flow cytometric analysis, cell proliferation assay, Western blotting and immunoprecipitation, colocalization studies by confocal immunofluorescence microscopy, RNA interference, and ex vivo tumor penetration assays are given in the Supplementary Materials and Methods.
Results
Design and generation of high-affinity NRP-binding Fc-A22p
To find an NRP-targeting peptide among human proteins, we analyzed the interactions between NRPs and their intrinsic ligands. Sema3A, as a disulfide-linked homodimer, interacts with two molecules each of NRP1 and plexinA1 for cellular signaling (Supplementary Fig.  S1C ; ref. 11). The C-terminal basic tail of furin-processed Sema3A is believed to bind to a cleft with negative charge in the b1 domain of NRPs, so-called C-terminal argininebinding pocket (17, 31) , as does the exon 8-encoded domain of VEGF165 (16) . Guided by the recent crystal structure of VEGF165/NRP1-b1 domain (32), we chose the C-terminal 22 residues of Sema3A (called A22), corresponding to residues 739-760 (31), as a targeting moiety for the C-terminal arginine-binding pocket of both NRP1 and NRP2 ( Supplementary Fig. S1D ). The A22 peptide was genetically fused to the C-terminus of human IgG1 Fc via a 15-residue (G 4 S) 3 linker, generating Fc-A22 (Fig. 1A) , which was intended to mimic the bivalent binding of Sema3 ligands to NRP1/2 (Fig. 1B) .
Fc-A22 purified from HEK293F cell cultures bound to soluble b1b2 domains of NRPs (NRP-b1b2) with affinity in the micromolar range (K D ¼ approximately 6-9 mmol/L; Supplementary Fig. S2A ), which was approximately 200-fold lower than that of Sema3A ( Fig. 1C ; Supplementary Table S1 ). To increase the binding affinity, we designed another peptide, called A22p, with the same sequence as A22 except for an Asn to Pro substitution (N758P) at the third residue from the C-terminus based on structural analysis of the VEGF165/NRP1-b1 domain ( Fig. 1A; ref. 32 ). VEGFs with a conserved Pro residue at this position instead of the Asn in Sema3s have an approximately 10-fold higher affinity for NRPs (Supplementary Fig. S1D and Supplementary Table S1 ). Fc-A22p, which was constructed in the same way as Fc-A22 (Fig. 1A) , was well expressed in the correctly assembled form in HEK293F cell cultures (Supplementary Fig. S2B and Supplementary Table S2 ). Fc-A22p bound to both NRP1-b1b2 and NRP2-b1b2 domains with an approximately 100-fold higher affinity (K D ¼ approximately 63 nmol/L) than that of Fc-A22 ( Fig. 1C ; Supplementary Table S1 ). In contrast, the synthesized A22p peptide alone bound very weakly to NRP-b1b2 even at 10 mmol/L (Fig. 1C) , suggesting that the bivalent binding format of Fc-A22p is critical for high-affinity binding due to the avidity effect. Fc-A22p did not cross-react with soluble VEGF-R2 protein (Fig. 1C ), but competed with VEGF165 and Sema3A for binding to both soluble NRP-b1b2 (Fig. 1D ) and cell surfaceexpressed NRPs in human ovarian cancer SK-OV-3 cells (Supplementary Fig. S3B ). This indicates that Fc-A22p specifically binds to NRPs, particularly to the argininebinding pocket in the NRP-b1 domain.
Fc-A22p specifically interacts with NRPs undergoing cellular internalization
Cellular internalization of NRP1/2 in response to their intrinsic ligands, such as VEGF165 and Sema3A, is essential for triggering intracellular signaling (14, 33) . When FcA22p was incubated at 37 C for 30 minutes with HUVECs and SK-OV-3 tumor cells, it was internalized into the cells and colocalized with NRP1 and NRP2 as well as the early endosomal marker EEA1 ( Fig. 1E; Supplementary Fig.  S3C and S3D ), suggesting that Fc-A22p may act as an agonist to NRPs (9). However, Fc-A22p did not cause any significant cytotoxicity on NRP1/2-expressing HUVECs, SK-OV-3, FaDu, and A431 cells during 72-hour incubation ( Supplementary Fig. S4 ).
We further analyzed the molecular components that interact with Fc-A22p by immunoprecipitating FcA22p from cell lysates of Fc-A22p-treated HUVECs, and compared it with Fc and Sema3A. Sema3A physically interacted with NRP1 and plexinA1, but not with NRP2 or VEGF-R2 (Fig. 1F) , confirming the ligand binding specificity on the cell surface (13) . However, Fc-A22p pulled down NRP1 and NRP2, but not VEGF-R2 or plexinA1 (Fig.  1F) , suggesting that Fc-A22p only binds to NRPs.
Fc-A22p homes to tumor vessels and penetrates extravascular tumor tissues
Human head and neck squamous carcinoma FaDu cells express both NRP1 and NRP2 (Supplementary Fig.  S3A ). Mouse and human NRP1 and NRP2 share high sequence homology (93% and 95%, respectively; ref. 14) , particularly with 100% conserved the C-terminal arginine-binding pocket in the b1 domain (17) . To determine whether Fc-A22p localizes to and penetrates into tumors, a single dose of Fc-A22p was injected intravenously into mice with preestablished FaDu tumors. After 3 and 12 hours of circulation, tumors were excised and sectioned, and then the localization of Fc proteins in relation to blood vessels was determined by immunofluorescence staining. Compared with Fc, Fc-A22p was significantly detected in and around tumor vessels as early as after 3 hours of circulation and after 12 hours of circulation and it was even inside the tumor tissue far from the vessels (Fig. 2A) . Quantification of the Fc protein-positive areas revealed that the distribution of Fc-A22p in the tumor tissues was more than 2-fold higher than that of Fc. Fc-A22p was colocalized with NRP1/2 on the tumor vessels and tissues in which NRP1 and NRP2 were abundantly expressed (Fig. 2B) . Similar results were obtained in mice bearing human epidermoid carcinoma A431 xenografts (Supplementary Fig. S5A ). Fc-A22, which has the lower-affinity A22 peptide fused to Fc, also exhibited tumor homing and penetration at 3 hours postinjection, but less efficiently than Fc-A22p. In contrast, the monovalent A22 and A22p peptides were not detected in the tumor tissues ( Supplementary Fig. S5A ).
Fc-A22p enhances vascular permeability in endothelial cells through NRP-dependent downregulation of vascular endothelial cadherin
The efficient extravasation of Fc-A22p in the xenografted tumors prompted us to determine whether Fc-A22p increases vascular permeability in an in vitro transendothelial permeation assay using HUVECs. FcA22p enhanced passage of FITC-dextran through HUVEC monolayers by more than 3-fold, and was similar to that of VEGF165 and Sema3A, whereas the Fc-mediated enhancement was negligible (Fig. 3A) . NRP1/2 knockdown by siRNAs demonstrated that the induced endothelial permeability of Fc-A22p was dependent on NRP1/ 2 (Fig. 3A) . The ability of Fc-A22p to induce tumor vascular permeability was further assessed in vivo by the extravasation of Evans blue dye coinjected intravenously into mice bearing FaDu tumors. Similarly to the wellknown vascular permeability-inducing ligands Sema3A and VEGF165 (12, 13) , coadministration of Fc-A22p increased the accumulation of Evans blue dye in tumors by approximately 2-fold compared with coadministration of Fc (Fig. 3B) .
Vascular endothelial (VE)-cadherin acts as endothelial barrier by maintaining adherent junctions between cells, and its downregulation is closely correlated with cell-cell junction destabilization and elevated endothelial permeability (12) . Treatment of Fc-A22p, but not Fc, downregulated VE-cadherin in HUVECs in an NRP1/2-dependent manner to levels similar to those of VEGF165 and Sema3A ( Fig. 3C and D; refs. 12, 19, 20) . The A22 and A22p peptides had no effects, and Fc-A22 had a lesser effect than Fc-A22p on VE-cadherin downregulation and transendothelial permeability in HUVECs (Supplementary Fig. S5B and S5C ). Like VEGF165 stimulation in HUVECs, Fc-A22p, but not Fc, markedly reduced the amount of VE-cadherin in the cell periphery and its colocalization with F-actin (Supplementary Fig. S6A ), suggesting the opening of endothelial cell-cell contacts (34) . Therefore, these results mirror those of the in vivo tumor extravasation assay ( Fig. 3B;  Supplementary Fig. S5 ).
Fc-A22p induces NRP-mediated E-cadherin downregulation in tumor cells and penetrates ex vivo tumor tissues
Because many tumor cells overexpress NRPs on their cell surface (Supplementary Fig. S3A; ref. 11) , we assessed the effects of Fc-A22p on E-cadherin, an epithelium-specific cell adhesion molecule, in tumor cells. E-cadherin is a principal component of the adherens junctions and is of particular importance to the limited tissue penetration of mAbs (4). Fc-A22p noticeably downregulated E-cadherin in FaDu and A431 cells in an NRP1/2-dependent manner ( Fig. 4A and B) and disrupted the integrity of cell-cell junctions ( Supplementary Fig. S6B ). However, Fc-A22p neither upregulated N-cadherin nor downregulated b-catenin, signaling involved in tumor invasion and metastasis (35, 36) . The monovalent peptides A22 and A22p did not affect E-cadherin levels in A431 cells (Supplementary Fig. S5D ).
The ability of Fc-A22p to downregulate E-cadherin prompted us to investigate whether Fc-A22p can actively penetrate into ex vivo tumor tissues. FaDu xenografts were excised from mice and incubated with Fc proteins for 2.5 hours at 37 C. Analysis of tumor sections revealed that Fc-A22p, but not Fc, penetrated more than 4 to 5 cell layers deep in 2.5 hours into the xenograft explants ( Supplementary Fig. S5E ), indicative of the relationship between tumor penetration activity and E-cadherin downregulation.
mAb-A22p antibodies bind to NRPs while retaining the intrinsic antigen-binding and Fc properties of the parent mAbs
To test the Fc-A22p platform for solid tumor-targeting mAbs, A22p was fused via a 15-residue (G 4 S) 3 linker to the C-terminus of the heavy chain of 2 clinically approved solid tumor-targeting mAbs, the anti-EGFR cetuximab (chimeric IgG1) and the anti-Her2 trastuzumab (humanized IgG1), generating mAb-A22p antibodies (cetuximabA22p and trastuzumab-A22p, respectively; Fig. 5A ). Expression of mAb-A22p antibodies by transient transfection into HEK293F cells yielded similar production levels to those of the parent mAbs ( Supplementary Fig.  S7A and Supplementary Table S2 ). The mAb-22p antibodies maintained their respective specific antigen-binding affinity and exhibited simultaneous binding to both the target antigen and the NRP-b1b2 domain (Supplementary Fig. S7B and Supplementary Table S3) . When incubated at 37 C with EGFR-negative, NRP1-expressing PPC-1 human prostate tumor cells, cetuximab-A22p was internalized into the cells and colocalized with NRP1, which was not observed with the parent cetuximab (Supplementary Fig. S7C ). Therefore, mAb-A22p can trigger NRP-mediated cellular internalization, which is indicative of NRP activation by mAb-A22p, as was observed with Fc-A22p (Fig. 1E) . Cetuximab-A22p exerted comparable inhibitory effects on the cell proliferation and EGFR activation to those of cetuximab, indicative of a neutral role of A22p in the in vitro biologic activities of cetuximabA22p (Supplementary Fig. S8 ). The mAb-A22p maintained the typical pH-dependent binding property for neonatal Fc receptor (FcRn; Supplementary Fig. S7D and Supplementary Table S3), which plays an important role in maintaining the serum half-lives of antibodies. The affinities of mAb-A22p binding to FcgRIIa, FcgRIIIa, and FcgRIIIb were also comparable with those of the parent mAbs (Supplementary Table S3 ).
mAb-A22p antibodies exhibit enhanced tumor homing and extravascular tumor penetration
We compared the tumor homing and intratumoral distribution of mAb-A22p with those of the parent mAbs by intravenously injecting them into mice harboring EGFR-overexpressing FaDu xenografts for cetuximab and Her2-overexpressing SK-OV-3 xenografts for trastuzumab and then immunofluorescent staining the tumor sections at 3 and 12 hours postinjection. The intratumoral accumulation and penetration of the mAbs increased with circulation time (Fig. 5B; Supplementary Fig. S9A ), in agreement with previous results (29, 30) . After equivalent circulation times, more noticeable extravasation and farther spreading from the blood vessels in tumor tissues was observed with the mAb-A22p antibodies, approximately 2-fold and 1.5-fold increases at 3 and 12 hours postinjection within the tumors, respectively, compared with the parent mAbs ( Fig. 5B; Supplementary Fig. S9A ). Similar results were obtained for cetuximab-A22p in EGFR-overexpressing A431 tumor xenografts ( Supplementary Fig.  S9C ). The extravasated cetuximab-A22p, but not cetuximab, colocalized with NRP1/2 in FaDu tumor tissues (Fig. 5C ). Quantitative analysis of the antibody levels in tumor lysates by Western blotting also confirmed a greater than 2-fold higher accumulation of mAb-A22p antibodies compared with the parent mAbs ( Fig. 5D ; Supplementary Fig. S9B ). The higher accumulation and farther spreading of cetuximab-A22p could be attributable to the more significant inhibition of EGFR phosphorylation in FaDu tumor tissues, compared with cetuximab (Fig. 5D ). Western blots of tumor tissue lysates revealed significant downregulation of E-cadherin at 3 and 12 hours postinjection in the mAb-A22p-injected tumors, but not in the mAb-injected tumors, for both the FaDu and SK-OV-3 xenografts ( Fig. 5D; Supplementary Fig.  S9B ). However, we observed no upregulation of N-cadherin, vimentin, or fibronectin, hallmark proteins associated with tumor invasion and metastasis (35) .
mAb-A22p antibodies exhibit superior in vivo antitumor efficacy compared with the parent mAbs To determine whether the enhanced intratumoral accumulation and penetration of mAb-A22p antibodies translates into increased therapeutic efficacy, we compared the in vivo antitumor efficacy of the mAb-A22p antibodies with that of the parent mAbs. Antibodies were intravenously administered at 2 different dosages into mice bearing At equivalent dose, the mAb-A22p antibodies exhibited higher antitumor activity from 3 days after the first injection, than the parent mAbs (Fig. 6) . The enhanced antitumor efficacy of mAb-A22p antibodies became more prominent at the lower dosage, showing an approximately 2-fold or greater reduction in tumor volume and weight by the end of treatment compared with the parent mAbs. Combined treatments of either cetuximab or trastuzumab with FcA22p exhibited similar tumor growth inhibition efficacy to that of the mAb-A22p antibodies but higher than that of the mAbs alone (Fig. 6 ), indicating that Fc-A22p improves the antitumor efficacy of the coadministered mAbs most likely by enhancing the tumor tissue penetration. Mouse body weight, which was monitored as an indicator of antibody toxicity, was similar between the mAb-and mAb-A22p-treated groups ( Supplementary Fig. S9F and S9G ).
Discussion
Here, we report the development of a superior solid tumor-targeting antibody format, mAb-A22p, by genetic fusion of high-affinity NRP-targeting A22p peptide to the C-terminus of heavy chain of the conventional mAbs. Due to the bivalent NRP-engaging activity, mAb-A22p antibodies exhibited much better tumor homing, extravasation from blood vessels, and accumulation with deep tissue penetration than the parent mAbs. These properties were directly linked to their superior antitumor efficacy in mouse xenograft models over that of the parent mAbs. Coadministration of mAbs with promoter agents was previously shown to augment the vascular permeability and/or penetration within tumor tissues, which significantly improved the in vivo antitumor efficacy (8, 10) . However, our approach of directly fusing a tumor-homing and tissue-penetrating peptide to solid tumor-targeting mAbs has not been previously reported.
The molecular mechanism underlying the enhanced tumor homing and tissue penetration of mAb-A22p is mediated by bivalent engagement of cell-surfaceexpressed NRP1/2, and the mechanism can be dissected into 3 sequential steps (Figs. 1-5 ): (i) tumor homing by targeting NRP1/2 overexpressed on tumor-associated endothelial cells, (ii) improved extravasation due to enhanced vascular permeability, and (iii) improved tissue penetration by reducing the epithelial barrier. Fc-/mAbA22p rapidly and extensively localized to tumor vessels compared with the respective parental format, suggesting that NRP1/2 serve as tumor-homing targets due to their overexpression, not only on tumor endothelium, but also on many types of cancer cells (11, 15) . Because NRP1/2 are also expressed at low levels in normal tissue vessels (11) , however, additional in vivo studies to address normal tissue distribution and any systemic cytotoxicity of Fc-/ mAb-A22p are necessary. Fc-A22p enhanced vascular permeability in endothelial cells through NRP-dependent downregulation of VE-cadherin, which explains the enhanced in vivo extravasation of Fc-/mAb-A22p into tumor parenchyma. Fc-A22p also penetrated into ex vivo tumor tissues, most likely due to the reduced epithelial barrier induced by NRP-mediated downregulation of Ecadherin. The difference in the antitumor efficacy between SK-OV-3 tumor treatments with trastuzumab-A22p and trastuzumab was more evident (approximately 3-fold) than that between FaDu tumor treatment with cetuximabA22p and cetuixmab (less than 2-fold) based on the tumor weight (Fig. 6 ). This could be attributed to the higher expression levels of NRP1/2 in SK-OV-3 cells than those in FaDu cells (Supplementary Fig. S3A ). However, the two mAb-A22p antibodies exhibited similarly enhanced levels (approximately 1.5-fold) of tumor tissue penetration compared with the parent mAbs ( Although Fc-A22p acted as an agonist of NRPs triggering its cellular internalization and exerting the biologic activities, the monovalent A22p peptide did not even at 100 mmol/L, suggesting that the bivalent engagement of NRP1/2 by Fc-/mAb-A22p is essential for effective NRPmediated signaling. Therefore, fusion of the NRP-targeting A22p to the heavy chain C-terminus of mAb seems to induce receptor dimerization by binding to the argininebinding pocket in the b1 domain of NRP1/2, mimicking the homodimeric binding of VEGF or Sema3 ligands to NRPs (15, 33) . VEGF-and Sema3A-induced vascular permeability is commonly dependent on NRP1 coreceptor, but also requires the signal transducing receptor of VEGF-R2 and plexin, respectively (12, 13) . Unlike Sema3A, which physically interacts with both NRP1 and plexinA1 receptor (13) , Fc-A22p engages only NRP1/2 (Fig. 1F) , most likely due to the absence of the additional Sema and Ig-like domains of Sema3A (Supplementary  Fig. S1C; ref. 15) . Previously, NRP1 promoted vascular permeability independently of VEGF-R2 (37) and the NRP-targeting iRGD peptides enhanced extravascular tumor penetration of coadministered agents (7) (8) (9) . Along with the previous results, our results suggest that NRP1 and/or NRP2 could transduce the signal to destabilize VE-cadherin and E-cadherin in endothelial and tumor cells, respectively, without its coreceptors. However, at this point we cannot completely exclude the possibility of the interactions of Fc-A22p with additional molecules other than NRP1/2, requiring further studies to clearly elucidate whether NRP1 and/or NRP2 have the independent signaling capacity without any involvement of the coreceptors. Therefore, the intracellular signaling mechanisms triggered by the interactions of Fc-A22p with NRP1/2 need to be elucidated in future studies.
Once extravasated into the tumor parenchyma from blood vessels, mAb-A22p antibodies may bind to NRPs expressed on cancer cells to trigger NRP-mediated Ecadherin downregulation in cell adherens junction, which seems to facilitate the intratumoral penetration and thus the therapeutic efficacy of the antibodies in mouse xenograft tumor models (4) . This is similar to that observed with the coadministration of JO-1 viral protein and cetuximab or trastuzumab (10) . In the epithelial-mesenchymal transition, tumor cells typically lose the epithelial marker E-cadherin and gain mesenchymal markers, such as vimentin and N-cadherin (35, 36) . Treatments with mAb-A22p antibodies only downregulated E-cadherin, but did not upregulate Ncadherin and vimentin in tumor tissues ( Fig. 5D ; Supplementary Fig. S9B ), suggesting that Fc-/mAb-A22p antibodies selectively reduce the epithelial barrier in tumor tissues without promoting invasion and metastasis (35, 36) . Nonetheless, additional in vivo studies are necessary to determine effects of Fc-/mAb-A22p on the tumor invasion and metastasis.
The mAb-A22p antibodies exhibited biochemical properties comparable with those of the parent mAbs, such as productivity in mammalian cells, antigen binding, and FcRn and FcgRs binding profiles, demonstrating that A22p can be fused to the C-terminal heavy chain of solid tumor-targeting mAbs without compromising their inherent properties. In addition to the direct effects of antigen binding, many anticancer mAbs, including cetuximab and trastuzumab, exert antitumor effects through immune cells, so-called antibody-dependent cell-mediated cytotoxicity (ADCC), in which the interactions between Fc and FcgRs are critical (1). mAb-A22p exhibited comparable FcgR binding properties with those of the parent mAb, suggesting that the ADCC function of mAb-A22p is conserved. The improved accumulation and distribution of mAb-A22p might also enhance the interactions between the mAbs and immune cells to improve their therapeutic efficacy (2) . Finally, the superior properties of mAb-A22p antibodies over conventional mAbs include better tumor penetration and improved antitumor efficacy at the same dose, which could potentially reduce resistance and/or relapse of tumors as well as side effects by lowering the therapeutic dose.
